Tracxn Research - BioPharma Report, May 2017

Biopharma - CNS Diseases – May 2017 Copyright © 2017, Tracxn Technologies Private Limited. All rights reserved.
Tracxn
World’s Largest Startup Research Platform
2

Contents
Topic Page No.
Scope of Report 04
Entrepreneur Activity 06
Investment Trend 08
Who is Investing 19
Exit Outlook - IPO, Acquisitions 23
Sub Sector Analysis 26
Interesting Companies 48
Company List 59
Team 173
3

Sector Overview
Scope of report
This report is an analysis of companies developing therapeutics for the treatment of CNS diseases, including,
neurodegenerative, pain, psychiatric disorders, and rare CNS diseases.
This report includes all companies developing antibodies, vaccines, small molecules, gene therapies, and cell therapies for
CNS Diseases. The report excludes big pharma companies, contract service providers, generic drug manufacturers and
platform companies.
This report includes all equity funding rounds, grants, awards, post-IPO equity and debt funding.
Disclaimer: The information and data in the report is based on global developments tracked in the sector till May 4, 2017. This is to categorically state that any events
and relevant developments after the said date will not reflect in the report.
4

Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
5
Contents

40
47 48
59 60
52
25
0
14
28
42
56
70
2010 2011 2012 2013 2014 2015 2016
#ofCompanies
YoY – Number of companies founded
6
Hua Medicine SAGE Therapeutics WAVE Life Sciences True North Therapeutics Ovid Therapeutics Denali Therapeutics Axial Biotherapeutics
AveXis Annexon Biosciences Prexton Therapeutics SA Alector Voyager Therapeutics Aptinyx Satsuma Pharmaceuticals

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
7
Contents

YoY – Number of Rounds and Total Funding
$0.5B
$1.0B
$1.1B
$0.8B $0.8B
$1.8B
$1.2B
$3.1B
$1.8B
49
95
124
106
136
162
169
186
162
0
40
80
120
160
200
0.0
0.7
1.4
2.1
2.8
3.5
2008 2009 2010 2011 2012 2013 2014 2015 2016
#ofRounds
FundingAmountin($B)
8

YoY – Number of Rounds by Stage
11 15
25 25
15
25
54
65
71
87
96 78
16
20
28
20
27
12
0
32
64
96
128
160
2011 2012 2013 2014 2015 2016
#ofRounds
Seed Early Late
9

YoY – Funding by Stage
$14M $11M $36M $25M $17M $16M
$442M
$315M
$356M
$472M
$1307M
$751M
$144M
$301M
$774M
$457M
$773M
$340M
0
500
1000
1500
2000
2500
2011 2012 2013 2014 2015 2016
TotalFundingin($M)
Seed Early Late
10

Average Ticket Size – Early Stage
$1.8M
$1.1M
$1.8M
$1.2M $1.5M $1.0M
$14.6M
$5.9M
$6.8M
$9.6M
$16.0M
$14.4M
$12.7M
$12.0M
$10.7M $10.1M
$25.8M
$17.6M
0.0
6.0
12.0
18.0
24.0
30.0
2011 2012 2013 2014 2015 2016
FundingAmountin($M)
Seed Series A Series B
11

Company
Funding
Amount
Round
Name
Date Investors
highlandtherapeutics.com
Highland Therapeutics
(Toronto, 2008)
$263M Series D Jan-2017
denalitherapeutics.com
Denali Therapeutics
(San Francisco, 2015)
$130M Series B Aug-2016
Baillie Gifford, ARCH Venture Partners, F-Prime Capital Partners, Alaska
Permanent Fund, Flagship Pioneering
biohavenpharma.com
Biohaven
Pharmaceutical
(New Haven, 2014)
$80M Series C Nov-2016
Venrock, RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs
Capital, Osage University Partners, Aperture Venture Partners, Connecticut
Innovations
aptinyx.com
Aptinyx
(Evanston, 2015)
$65M Series A May-2016
New Leaf Ventures, Frazier Healthcare Partners, Longitude Capital, Osage
University Partners, Adams Street Partners, Latterell Venture Partners,
Beecken Petty O'Keefe & Company, Northwestern University
huamedicine.com
Hua Medicine
(Shanghai, 2010)
$50M Series C Apr-2016
Harvest Investment Group LLC, Frontline BioVentures, ARCH Venture Partners,
Venrock, Fidelity Growth Partners Asia, WuXi Healthcare Ventures, TF Capital
proclarabio.com
Proclara Biosciences
(Cambridge, 2006)
$47M Series E Sep-2016
truenorthrx.com
True North Therapeutics
$45M Series D Oct-2016
HBM Healthcare Investments, Redmile Group, Perceptive Advisors, Franklin
Templeton
annexonbio.com
Annexon Biosciences
(Palo Alto, 2011)
$44M Series B Jun-2016 NEA, Correlation Ventures, Novartis Venture Fund, Clarus
12
Top investments in last one year

Company
Funding
Amount
Round
Name
Date Investors
acimmune.com
AC Immune
(Lausanne, 2003)
$44M Series E May-2016
arrakistx.com
Arrakis Therapeutics
(Waltham, 2015)
$38M Series A Feb-2017
Canaan Partners, Advent Life Sciences, Pfizer, Celgene, Osage University
Partners
cerevance.com
Cerevance
(Cambridge, 2015)
$36M Series A Dec-2016 Takeda Pharmaceutical Company, Lightstone Ventures
medday-pharma.com
MedDay
Pharmaceuticals
(Paris, 2011)
$34M Series B Apr-2016 Edmond de Rothschild Group, Bpifrance, Sofinnova Partners
recursionpharma.com
Recursion Pharma
(Salt Lake City, 2013)
$32M Series A Sep-2016
prextontherapeutics.com
Prexton Therapeutics SA
(Plan-les-ouates, 2012)
$31M Series B Feb-2017 FORBION, Seroba Lifesciences, Merck Ventures, Ysios Capital, Sunstone
methylationsciences.com
MSI Methylation
Sciences
(Burnaby, 2007)
$30M Series B Oct-2016 Quark Venture
pharma2b.com
Pharma Two B
(Rehovot, 2007)
$30M Series C Feb-2017 Israel Biotech Fund, JVC Investment Partners, JK&B Capital, Generali
13

Company
Funding
Amount
Round
Name
Date Investors
Neurona Therapeutics
$29M Series A Dec-2016 The Column Group
Lysosomal Therapeutics
(Cambridge, 2011)
$26M Series A Jan-2017
Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme
BioVentures, Roche, Partners Health Care Innovation
Cavion
(Charlottesville, )
$26M Series A Jan-2017 Lilly Ventures, Novartis Venture Fund, Enso Ventures
Ovid Therapeutics
(New York City, 2014)
$26M Series C Jan-2017
Axial Biotherapeutics
(Boston, 2016)
$19M Series A Nov-2016
Longwood Fund, Domain Associates, Kairos Ventures, Heritage Medical
Systems
Promentis
Pharmaceuticals
(Milwaukee, 2006)
$17M Series C Mar-2017 Orbimed, F-Prime Capital Partners, Aisling Capital, Golden Angels Investors
Advicenne
(Nimes, 2007)
$17M Series A Mar-2017 IRDI GESTION, Cemag Invest, Xiaomi, Bpifrance, IXO Private Equity
Adynxx
$16M Series B Jan-2017 Domain Associates, TPG
14

Company
Funding
Amount
Round
Name
Date Investors
Recursion Pharma
(Salt Lake City, 2013)
$15M Series A Sep-2016
Lux Capital, Obvious Ventures, EPIC Venture Fund, Data Collective, AME Cloud
Ventures, Wild Basin Investments
SiteOne Therapeutics
$15M Series B Jan-2017
Next Frontier Capital, 2M Companies, Mission Bay Capital, Sears Capital
Management
Neuraltus
(Palo Alto, 2009)
$15M Series C May-2016
Agilis Biotherapeutics
(Cambridge, 2013)
$13M Series B Feb-2017 Sands Capital Ventures
Satsuma
Pharmaceuticals
$12M Series A Jan-2017 RA Capital Management, TPG
Affiris
(Vienna, 2004)
$11M Series B Jun-2016 MIG AG
Centrexion Therapeutics
(Baltimore, 2013)
$11M
Convertible
Debt
Jun-2016
Heptares
(Welwyn Garden City,
2007)
$10M Series B Jul-2016 Astrazeneca
15

Company
Funding
Amount
Round
Name
Date Investors
eXIthera
(Westborough, 2012)
$10M Series B May-2016
Promentis
Pharmaceuticals
(Milwaukee, 2006)
$9M Series C Sep-2016
Concentric Analgesics
$8M Series A Dec-2016
Vapogenix
(Houston, 2007)
$8M Series C Dec-2016 Pamoja Capital
Cortexyme
$8M Series A Apr-2017 Pfizer, Takeda Ventures, Breakout Labs
PamBio
(Nazareth, 2014)
$7M Series A Jul-2016
Centrexion Therapeutics
(Baltimore, 2013)
$7M
Convertible
Debt
Apr-2016
Amylyx Pharmaceuticals
(Cambridge, 2013)
$5M Series A Aug-2016 ALS Investment Fund, Morningside Group
16

Funnel view of Sector
Percent of
Previous
78%
42%
63%
141
111
171
271
644
828
0 180 360 540 720 900
M&A & IPO
Late
Series B
Series A
Funded
Founded
# of Companies
17

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
18
Contents

Most Active Investors in Sector
35
20
17
15
14 14
13 13
12 12
0
8
16
24
32
40
National
Institutes
of Health
Orbimed The Michael J.
Fox Foundation
Venrock Alta Partners Novartis
Venture Fund
NEA New Leaf
Ventures
HTGC MPM Capital
TotalNumberofCompanies
19
Cerecor Biotie
Cognition
Therapeutics
Zogenix Trevena Kalypsys Trevena Kalypsys UniQure
True North
Therapeutics
Recursion
Pharma
True North
Therapeutics
Civitas
Therapeutics
Hua Medicine FoldRx Acorda Targacept
True North
Therapeutics
Concert
Pharma
Xanodyne
Pharmaceuticals

Where are Top Investors investing
20

Top Investor by Stage of Entry
21

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
22
Contents

Date Company Acquirer
Deal
size
Overview
Total
Funding
Mar-2017
Neurovance
(Cambridge, 2011)
otsuka-us.com
Drug to modulate neurochemicals to treat Attention Deficit
Hyperactivity Disorder .
Venture Investors, GBS Venture Partners, Tekla Capital
Management, Novartis Venture Fund, SWIB (State of Wisconsin
Investment Board)
$26.3M
Feb-2017
CoLucid Pharmaceuticals
(Cambridge, 2005)
lilly.com $960M
Therapies for central nervous system disorders such as
migraine.
Auriga Partners, Novo A/S, Domain Associates, Pappas
Ventures, Triathlon Medical Ventures, Care Capital, Pearl
Street Venture Funds, TVM Capital, Pappas Capital
$96.1M
Dec-2016
Acetylon
(Boston, 2008)
celgene.com
Developing of next-generation, selective histone deacetylase
(HDAC) enzyme inhibitors
Celgene, The Kraft Group
$138.3M
Oct-2016
Vitae Pharma
(Fort Washington, 2001)
allergan.com $639M
Clinical stage company that develops novel drugs for various
diseases using proprietary drug design platform contour
NEA, Atlas Venture, Intel Capital, Venrock, Silicon Valley Bank,
Wellcome Trust, Prospect Venture Partners, Oxford Finance,
Foresite Capital
$94M
Sep-2016
Raptor Pharma
(Novato, 2006)
horizonpharma.
com
Raptor Pharmaceuticals
HealthCare Royalty Partners, Investor Growth Capital
$7M
Jul-2016
Bamboo Therapeutics
(Chapel Hill, 2014)
pfizer.com $150M
Gene therapies to treat rare central nervous system and
neuromuscular diseases.
CureDuchenne
$49.5M
23
Major Acquisitions in last one year

Biopharma - CNS Diseases – May 2017 Copyright © 2017, Tracxn Technologies Private Limited. All rights reserved.24
Major Acquisitions in last one year

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
25
Contents

April 2017Tracxn BlueBox: Biopharma – CNS Diseases
820+ companies in the sector, 380+ funded in last 5 years, $2.7B invested in 2016-17 YTD
26

Top Business Models by Funding
$5.2B
$3.5B
$2.8B
$1.4B $1.3B
0.0
1.2
2.4
3.6
4.8
6.0
Neurodegenerative Pain Psychiatry Others Rare CNS
TotalFundingin($B)
Avg. Age Aug-06 Jan-05 Aug-05 Jun-06 Jan-08
27
# Cos. 329 181 133 126 59
Denali Therapeutics Ethypharm Highland Therapeutics ReNeuron Group UniQure
Samumed Kalypsys Jazz Pharmaceuticals Acorda True North Therapeutics

Neurodegenerative – Business Model Description

Neurodegenerative – Key Trends
29

Neurodegenerative – Most Funded Companies

Pain – Business Model Description

Pain – Key Trends
32

Pain – Most Funded Companies

Psychiatry – Business Model Description

Psychiatry – Key Trends
36

Psychiatry – Most Funded Companies

Others – Business Model Description

Others – Key Trends
40

Others – Most Funded Companies

Rare CNS – Business Model Description

Rare CNS – Key Trends
44

Rare CNS – Most Funded Companies

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
47
Contents

Interesting Unfunded Companies
Company Overview Business Model
ENCEFA
(2016, Paris)
French early-stage biotech developing a neuro-protective small molecule
for Parkinson's disease
Neurodegenerative > Small Molecule
Avena Therapeutics
(2011, Dublin)
Irish, early-stage Biotech developing siRNA therapy for CNS applications Others > Gene Therapy
Hemadvance
(2015, St. Louis)
Protein therapeutics to diagnose, manage and treat the onset and
progression of coagulation disorders.
Others > Protein Therapy
Curated list of companies by the sector analyst are defined as Interesting

Interesting Seed Companies

Interesting Series A Companies

Interesting Series B Companies

Interesting Late Stage Companies

Top Funded Deadpooled Companies

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
58
Contents

Biopharma - CNS Diseases – List of Companies
Neurodegenerative Pain Psychiatry Others Rare CNS
644 FUNDED COMPANIES AND 184 UNFUNDED COMPANIES
COVERS THE FOLLOWING SECTORS

Neurodegenerative (1/44)
Total
Funding
paytm.com
iPierian, Inc.
(2007, Francisco)
Developing monoclonal antibodies against targets of the Tau protein as a
therapy for neurodegenerative diseases
Highland Capital Partners, KPCB, Google Ventures, Mitsubishi UFJ Capital,
SR One, MPM Capital, ATEL Capital Group, Biogen, Mission Bay Capital
Cell Therapy & Regenerative
Medicine
$74.20M
BrainStorm Cell
(2004, Petah Tikva)
Autologous stem cell therapies for the treatment of neurodegenerative
diseases such as ALS, MS, PD
portalsaude.saude.gov.br
Medicine
$12.30M
Q Therapeutics
(2004, Salt Lake City)
Develops human cell-based therapeutics for neurodegenerative diseases.
Vispring, EPIC Venture Fund, Invitrogen, SLLSA, Toucan Capital, Signal
Peak
Medicine
$12.00M
Neuralstem
(1996, Germantown)
Stem cell therapies for CNS diseases.
HTGC
Medicine
$5.00M
GeneGrafts
(2003, Haifa)
Cell-therapy for neurological disorders and cardiac arrhythmias.
SCP Vitalife Partners, ProSeed Venture Capital Fund
Medicine
$800.00K
Cell Reprogramming &
Therapeutics
(2013, Greenfield)
Somatic cell-based therapies for CNS disorders Cell Therapy & Regenerative
Medicine
StemGenex
(2007, La Jolla)
Company that offers adipose tissue stem cell therapy to patients with
degenerative diseases
Medicine
Living Cell Technologies
(1999, Auckland)
Cell therapy for neurodegenerative diseases
Angel HQ
Medicine
Go to BM List >> Pain

Total
Funding
paytm.com
Neurogeneration
(1996, Beverly Hills)
Early stage biotherapeutics company using autologous stem cells for
Parkinson's and other diseases
Medicine
Saneron CCEL
(1993, Tampa)
Early stage neurological and cardiac cell biotherapy company with 2
stem cell platforms
National Institutes of Health
Medicine
Blue Rock Therapeutics
(2016, Boston)
Induced pluripotent stem cell (iPSC) therapies for cardiovascular,
neurological diseases.
Medicine
NyaCell Therapeutics
(2016, Belmont)
Stem cell-based therapy for Parkinson's disease.
MassBio
Medicine
Medipost
(2000, Seongnam-si)
Stem cell based therapeutics Cell Therapy & Regenerative
Medicine
Voyager Therapeutics
(2014, Cambridge)
Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS.
Brookside Capital, Third Rock Ventures, Casdin Capital, Deerfield,
Wellington Management, Partner Fund Management
Gene Therapy $105.00M
GenSight Biologics
(2011, Paris)
Gene Therapy for Retinal Neurodegenerative Diseases.
Index Ventures, Versant Ventures, Abingworth, Healthcap, Jennison
Associates, Healthcap, Novartis Venture Fund, Perceptive Advisors, Sphera
Global Healthcare, Ibionext, Medicxi
Ceregene
(2001, San Diego)
Develops AAV-based therapies for neurodegenerative and eye disorders
Investor, California Technology Ventures, MPM Capital, Alta Partners, Cell
Genesys, Hamilton BioVentures, Hamilton BioVentures

Total
Funding
paytm.com
Neurologix
(1999, Fort Lee)
Develops therapeutic treatments for disorders of the brain and central
nervous system
Palisade Capital, Corriente Advisors
Gene Therapy $7.00M
nLife Therapeutics
(2010, Armilla)
Oligonucleotide-based therapies for Parkinsons's disease and other CNS
disorders
Caixa Capital Risc, Cross Road Biotech
Gene Therapy $6.60M
American Gene
(2007, Rockville)
Develops lentivirus therapies for the treatment of cancer and other
chronic human diseases
National Institutes of Health
Gene Therapy $2.83M
Brain Vectis
(2015, Paris)
Gene therapies for the treatment of Alzheimer and Huntington disease
by targeting brain cholesterol metabolism. Gene Therapy $1.10M
Lazarus Therapeutics
(2006, Malvern)
Therapies for patients at various stages of Parkinson's diseases.
Ben Franklin Technology Partners
Gene Therapy $100.00K
Oxford BioMedica
(1995, Oxford)
Gene therapies to treat multiple ocular, CNS diseases and
vaccines/antibodies to treat different cancer. Gene Therapy
Brendinn Therapeutics
(2014, Amsterdam)
microRNAs therapeutics for neurodegenerative diseases
Gene Therapy
LifeSplice Pharma
(2011, Malvern)
Splice-modulating oligomers for the treatment of neurological disorders
Gene Therapy

Pain (1/24)
Total
Funding
paytm.com
Carbylan
(2004, Palo Alto)
Therapeutics using polymers of hyaluronic acid for pain management.
InterWest Partners, Alta Partners, Vivo Capital
Medicine
$33.90M
Ribomic
(2003, Minato)
Aptamer-based therapeutics
Nippon Venture Capital, Bio-sight Capital, Nagoya Small and Medium
Business Investment & Consultation Co
Gene Therapy $4.12M
PeriphaGen
(2012, Pittsburgh)
Neuronal gene delivery products to treat neurological disorders
RA Capital Management
Gene Therapy
Benitec Biopharma Limited
(1997, Sydney)
ddRNAi technology based drugs for infectious, ocular and genetic
diseases Gene Therapy
Nurel Therapeutics
(2003, Stockholm)
Developing gene therapies for the treatment of pain
Gene Therapy
BeRNA Therapeutics
(2014, Boston)
Develops and delivers biologic drugs to cure pain transcutaneously.
Gene Therapy
Cerimon Pharmaceuticals
(2004, San Francisco)
Developing therapeutics for autoimmune disease, inflammation, and
pain
Orbimed, MPM Capital, Phase4 Partners
Immunotherapy $72.73M
Kineta
(2008, Seattle)
Developing immune-modulating therapeutics and vaccine adjuvants for
autoimmune and infectious diseases
Keiretsu Forum, AngelMD, RLB Holdings, Keiretsu Capital, Keiretsu Forum,
National Institute of Allergy and Infectious Diseases, The Iacocca Family
Foundation
Neurodegenerative << Go to BM List >> Psychiatry

Pain (2/24)
Total
Funding
paytm.com
Tetragenetics
(2011, Ithaca)
Developing antibody-based drugs for autoimmune diseases and pain
using its ion channel technology
National Institutes of Health, Department of Energy (US), Excell Partners,
United States Department of Defense, Grand Challenges, HHS
Regeneron Pharmaceuticals
(1998, Tarrytown)
Antibodies for the treatment of cancer, eye diseases, inflammatory
diseases, pain, cardiovascular diseases and allergic conditions.
Sanderling Ventures, Tekla Capital Management
Immunotherapy
Rinat Neurosciences
Antibody therapeutics for CNS diseases
Essex Woodlands, Prospect Venture Partners, SV Life Sciences
Immunotherapy
Symberix
(2010, Durham)
Microbiome-targeted therapeutics for pain and cancer.
Microbiome Therapy
Levicept
(2012, Sandwich)
Novel biological for the treatment of chronic pain
Index Ventures, Advent Venture Partners, Gilde Healthcare, Advent Life
Sciences, Innovate UK, Medicxi
Protein Therapy $12.72M
Xalud Therapeutics
Protein therapeutics for chronic pain
National Institutes of Health, PBM Capital Group
Hoba Therapeutics
(2016, Copenhagen)
Developing a new therapeutic protein for the treatment of neuropathic
pain.
Novo A/S, Borean Innovation
Manzanita Pharmaceuticals
(2007, Woodside)
Developing non-opiate, pen-injectable protein-drug conjugates
(glucocorticoids+NGF) to treat chronic pain Protein Therapy

Pain (3/24)
Total
Funding
paytm.com
Theralpha
(2009, Valbonne)
Snake venom derived peptides as therapeutics for pain management
Protein Therapy
EuMederis
Pharmaceuticals
(2009, San Diego)
Peptide therapeutics for indications in pain and in control of
osteoporosis Protein Therapy
Anygen
(2000, Gwangju)
Peptide API and drug developer for cancer & pain disorders
Korea Investment Partners, Solidus Investments
Protein Therapy
Ethypharm
(1977, Saint-cloud)
Pharmaceutical company specializing in treatment of pain and addiction
Biovail, PAI Partners, Astorg Partners
Small Molecule $248.09M
Kalypsys
(2001, San Diego)
Clinical stage pharmaceutical company engaged in drug discovery and
development
New Leaf Ventures, Sprout Group, KT Venture Group, 5AM Ventures, Aravis,
Tavistock Group, EDB, Lombard Odier, CMEA Ventures, Novartis Venture
Fund
Zogenix
(2006, San Diego)
Developing drug delivery systems for treatment of CNS disease.
Venrock, Scale Venture Partners, Thomas, McNerney & Partners,
Abingworth, Domain Associates, Life Science Angels, Oxford Finance,
Chicago Growth Partners, Clarus
Trevena
(2007, King Of Prussia)
Biased GPCR ligand technology based therapeutics for cardiovascular
diseases and pain
Forest Laboratories, NEA, Polaris Partners, Alta Partners, Healthcare
Ventures

Pain (4/24)

Pain (5/24)

Pain (6/24)

Pain (7/24)

Pain (8/24)

Pain (9/24)

Pain (10/24)

Pain (11/24)

Pain (12/24)

Pain (13/24)

Pain (14/24)

Pain (15/24)

Pain (16/24)

Pain (17/24)

Pain (18/24)

Pain (19/24)

Pain (20/24)

Pain (21/24)

Pain (22/24)

Pain (23/24)

Pain (24/24)

Psychiatry (1/18)
Total
Funding
paytm.com
miCure Therapeutics
(2013, Ness Ziona)
Developing microRNA therapeutics and diagnostics for CNS disorders
Gene Therapy $2.00M
Nabi Biopharmaceuticals
(1967, Rockville)
Preventive drug for nicotine addiction
Immunotherapy
Neurogenic
(1995, Rehovot)
ELISA test & immune suppressants for the diagnosis & treatment of
schizophrenia Immunotherapy
InterveXion
(2005, Little Rock)
Antibody-based therapies for METH abuse
NIDA
Immunotherapy
AB-Biotics
(2010, Barcelona)
Developing probiotic drugs for dental disorders and providing genetic
analyses for pharmacogenetic studies
Almirall, Institut Catala de Finances (ICF)
Microbiome Therapy $6.59M
Portage Biotech
(2013, Toronto)
Therapeutics based on Cell Permeable Peptide Platform
Psylin Neurosciences
(2007, San Diego)
Develops peptide therapeutics for the treatment of psychiatric disorders.
Protagenic
(2004, New York City)
Develops neuropeptides for the treatment of anxiety and depression
based mood disorders Protein Therapy $2.02M
Pain << Go to BM List >> Others

Psychiatry (2/18)
Total
Funding
paytm.com
Iproteos
(2011, Barcelona)
Peptidomimetic therapeutics for CNS disorders and cancer
Caixa Capital Risc, Kinled, CapitalCell, Ascil Biopharm
Highland Therapeutics
(2008, Toronto)
Emerging Pharma company developing improved versions of pre-
approved drugs using proprietary drug delivery system DELEXIS
Citi
Jazz Pharmaceuticals
(2003, Dublin)
Develops & commercializes products in areas of narcolepsy, oncology,
pain and psychiatry.
KKR & Co. L.P, Adams Street Partners, Golden Gate Capital, Lehman
Brothers, Oak Hill Capital Partners, Versant Ventures, Prospect Venture
Partners, Longitude Capital, Beecken Petty O'Keefe & Company, EGS
Healthcare Capital Partners, Investor Growth Capital
Small Molecule $272M
Naurex
(2008, Evanston)
Clinical-stage company developing novel therapies for depression and
other CNS disorders.
Northwestern University, Adams Street Partners, Shire, Baxter, Latterell
Venture Partners, Cowen, Genesys Capital, Phoenix IP Ventures, Lundbeck,
Savitr Capital, Takeda Ventures, druidbio.com, EcoR1 Capital, Portola
Capital Partners
Targacept
(1997, Winston-salem)
Neuronal nicotinic receptors (NNR) therapies for the treatment of CNS
and GI/GU disorders.
NEA, Jafco Ventures, Advent Venture Partners, Burrill and Company,
Easton Capital, Oxford Bioscience Partners, Nomura Holdings, CDC
Innovation, CDIB BioScience Venture, EuclidSR Partners, Phase4 Partners,
Bison Capital Asset Management, Innovation Capital, Advent Life Sciences,
Auriga Partners

Psychiatry (3/18)

Psychiatry (4/18)

Psychiatry (5/18)

Psychiatry (6/18)

Psychiatry (7/18)

Psychiatry (8/18)

Psychiatry (9/18)

Psychiatry (10/18)

Psychiatry (11/18)

Psychiatry (12/18)

Psychiatry (13/18)

Psychiatry (14/18)

Psychiatry (15/18)

Psychiatry (16/18)

Psychiatry (17/18)

Psychiatry (18/18)

Others (1/17)
Total
Funding
paytm.com
ReNeuron Group
(1997, Guildford)
Stem cell-based therapeutics for Stroke Disability, Critical Limb
Ischaemia, Retinitis Pigmentosa and provider of stem cell lines.
Medicine
$216.00M
International Stem Cell
Corp.
(2001, Carlsbad)
Regenerative medicine for ophthalmology, neurology and liver disease Cell Therapy & Regenerative
Medicine
$34.41M
Neurona Therapeutics
Transplantation of stem cells secreting (GABAergic) interneurons for
epilepsy, neuropathic pain, spasticity and certain cognitive impairments
and psychoses cells
The Column Group
Medicine
$28.78M
Stemedica
(2005, San Diego)
Develops and manufactures ischemic-tolerant allogeneic stem cells Cell Therapy & Regenerative
Medicine
$22.00M
Athersys
(1995, Cleveland)
Stem Cell Therapy for the treatment of diseases and conditions in the
cardiovascular, neurological, inflammatory disease areas.
Orbimed, Western Technology Investment, EDBI, Invesco, Pappas Ventures,
RA Capital Management, Radius Ventures, NeoMed Management, Greenleaf
Capital Partners, LLC, Costella Kirsch, Van Wagoner Capital Management
Medicine
$9.00M
Axonia Medical
(2011, Kalamazoo)
Tissue engineered nerve grafts.
Southwest Michigan First, Ann Arbor SPARK
Medicine
$2.00M
California Stem Cell
(2005, Irvine)
Human cells manufacturer & stem cell based therapy for CNS and cancer
disorders
Medicine
$1.95M
Psychiatry << Go to BM List >> Rare CNS

Others (2/17)
Total
Funding
paytm.com
RhinoCyte
(2005, Louisville)
Diagnostics and stem cell therapies for CNS diseases.
Queen City Angels, KSTC, Kentucky Seed Capital Fund
Medicine
$1.90M
Oxygen Therapy
Early Stage biopharma company developing anti-necrosis drugs for
conditions resulting from Ischemia
Medicine
$300.00K
SanBio
(2001, Mountain View)
Regenerative therapies for neurological disorders
Western Technology Investment, Yet2ventures
Medicine
Juno Biomedical
(2014, Mountain View)
Regenerative medicine company that develops patient-centric medical
devices and therapies for neurological related disorders.
Medicine
DaVinci Biosciences
(2008, Yorba Linda)
Stem cell therapies for wide range of diseases Cell Therapy & Regenerative
Medicine
Xcelthera
(2013, San Diego)
early stage biotech working towards clinical development of stem cell
therapy for neurological and cardiovascular diseases
Medicine
StemGenn
(2014, Delhi)
Stem cell therapy for neurological, autoimmune and anti-aging disorders Cell Therapy & Regenerative
Medicine
Proneuron Biotechnologies
Developing neuroimmunological therapies to treat CNS diseases
Giza Venture Capital, Infinity Group, Swanlaab, Giza Venture Capital
Medicine

Others (3/17)

Others (4/17)

Others (5/17)

Others (6/17)

Others (7/17)

Others (8/17)

Others (9/17)

Others (10/17)

Others (11/17)

Others (12/17)

Others (13/17)

Others (14/17)

Others (15/17)

Others (16/17)

Others (17/17)

Rare CNS (1/8)
Total
Funding
paytm.com
StemCells
(1992, Newark)
Stem cell based therapeutics for CNS disorders. Cell Therapy & Regenerative
Medicine
UniQure
(1998, Amsterdam)
Developing gene-based therapies for patients with genetic or acquired
diseases.
Advent Venture Partners, HTGC, Omnes Capital, FORBION, Bristol-Myers
Squibb, Coller Capital, Gilde Healthcare, Advent Life Sciences
WAVE Life Sciences
(2012, Boston)
Develops Oligonucleotide-based medicines to treat rare genetic diseases.
Fidelity Investments, New Leaf Ventures, RA Capital Management, Jennison
Associates, Foresite Capital, SNBL USA, Redmile Group, Clough Global
AveXis
(2010, Deerfield)
Gene therapy for neurological genetic diseases such as spinal muscular
atrophy.
Venrock, T. Rowe Price, Janus Capital Group, Roche, RA Capital
Management, Tavistock Group, Third Security, Adage Capital Management,
QVT Financial, Deerfield, Foresite Capital, Rock Springs Capital, RTW
Investments, PBM Capital Group
Sangamo BioSciences
(1995, Richmond)
Developing Zinc finger nuclease based therapeutics for monogenic
diseases and HIV
Foresite Capital
Bamboo Therapeutics
(2014, Chapel Hill)
Gene therapies to treat rare central nervous system and neuromuscular
diseases.
CureDuchenne
Agilis Biotherapeutics
(2013, Cambridge)
Engineering DNA Therapeutics for Rare CNS Diseases.
Third Security, Sands Capital Ventures
Others << Go to BM List

Rare CNS (2/8)

Rare CNS (3/8)

Rare CNS (4/8)

Rare CNS (5/8)

Rare CNS (6/8)

Rare CNS (7/8)

Rare CNS (8/8)

Scope of Report
Investment Trend
Who is Investing
Sub Sector Analysis
Company List
Team
172
Contents

Team
173
Shubham Garg
Senior Analyst, Life Sciences
Ranjita Ravi
Lead Analyst, Life Sciences

Any and all information either accessed from the website www.tracxn.com or having otherwise originated from Tracxn Technologies Private Limited including but not limited to the
information contained herein ("Data") is the sole property of Tracxn Technologies Private Limited (hereinafter "Tracxn"). You shall not recirculate, distribute, transmit, publish, or sell
the Data or any portion thereof in any form or by any means, either for commercial or non-commercial use, or permit any third party to use or distribute the Data or any portion
thereof; to any other party, except with the prior written consent of Tracxn. You may however incorporate insubstantial portions, extracts, abstracts or summaries from the Data into
analysis, presentations or tools for your customers or for your internal use, so long as Tracxn is clearly and visibly identified as the source of information.
Further information please refer to our Terms of Use at www.tracxn.com Copyright © 2017, Tracxn Technologies Private Limited. All rights reserved.

Tracxn Research - BioPharma Report, May 2017

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Tracxn Research - BioPharma Report, May 2017

Similar to Tracxn Research - BioPharma Report, May 2017 (20)

More from Tracxn

More from Tracxn (20)

Recently uploaded

Recently uploaded (20)

Tracxn Research - BioPharma Report, May 2017